Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.89 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.89 |
| ▸ | PPARG | P37231 | 11/20 | 0.52 |
| ▸ | PPARA | Q07869 | 11/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947359 | 0.94 | S1PR1 (1.00) | S1PR1S1PR3PPARGPPARAFFAR1 | |
| Trifluoroacetic Acid SCHEMBL1869771 | 0.92 | S1PR1 (0.74) | S1PR1S1PR3PPARGPPARASIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL1876790 | 0.91 | S1PR1 (0.73) | S1PR1S1PR3PPARGPPARAFFAR1 | |
| Trifluoroacetic Acid SCHEMBL1876069 | 0.88 | S1PR1 (0.69) | S1PR1S1PR3PPARGPPARASIGMAR1 | |
| SCHEMBL950082 | 0.88 | S1PR1 (0.74) | S1PR1S1PR3PPARGPPARASIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL1873277 | 0.87 | S1PR1 (0.67) | S1PR1S1PR3PPARGPPARAFFAR1 | |
| SCHEMBL676680 | 0.80 | S1PR1 (0.74) | S1PR1S1PR3PPARGPPARAFFAR1 | |
| SCHEMBL14944081 | 0.80 | S1PR1 (0.74) | S1PR1S1PR3PPARGPPARAFFAR1 | |
| Trifluoroacetic Acid SCHEMBL1874106 | 0.80 | S1PR1 (0.57) | S1PR1S1PR3SIGMAR1 | |
| SCHEMBL1876791 | 0.79 | S1PR1 (0.61) | S1PR1S1PR3PPARGPPARASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-8791159-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD (JP) | 2011-01-27 | — | — | US | disclosed |
| US-7825109-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1661881-A2 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885PPARG 2805/4885 |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885PPARG 3532/4885 |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885PPARG 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.